Abstract
234 (PB222): Rational combination of pan-TEAD inhibitor SW-682 and MEK inhibitor mirdametinib in head and neck squamous cell carcinomas leads to synergistic response
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have